No abstract available
Keywords:
Combination targeted therapies; EGFR TKI; Lung cancer; MET amplification; Resistance.
MeSH terms
-
Acrylamides / administration & dosage
-
Adenocarcinoma of Lung / genetics
-
Adenocarcinoma of Lung / pathology
-
Adenocarcinoma of Lung / therapy*
-
Adult
-
Aged
-
Aniline Compounds / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Brain Neoplasms / genetics
-
Brain Neoplasms / secondary
-
Brain Neoplasms / therapy*
-
Crizotinib / administration & dosage
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics
-
Female
-
Humans
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology
-
Lung Neoplasms / therapy*
-
Male
-
Middle Aged
-
Mutation*
-
Prognosis
-
Proto-Oncogene Proteins c-met / antagonists & inhibitors*
Substances
-
Acrylamides
-
Aniline Compounds
-
osimertinib
-
Crizotinib
-
EGFR protein, human
-
ErbB Receptors
-
MET protein, human
-
Proto-Oncogene Proteins c-met